These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32034120)

  • 1. Replication and ribosomal stress induced by targeting pyrimidine synthesis and cellular checkpoints suppress p53-deficient tumors.
    Hubackova S; Davidova E; Boukalova S; Kovarova J; Bajzikova M; Coelho A; Terp MG; Ditzel HJ; Rohlena J; Neuzil J
    Cell Death Dis; 2020 Feb; 11(2):110. PubMed ID: 32034120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells.
    Lafita-Navarro MC; Venkateswaran N; Kilgore JA; Kanji S; Han J; Barnes S; Williams NS; Buszczak M; Burma S; Conacci-Sorrell M
    PLoS Genet; 2020 Nov; 16(11):e1009117. PubMed ID: 33201894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
    Massey AJ
    Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.
    King C; Diaz H; Barnard D; Barda D; Clawson D; Blosser W; Cox K; Guo S; Marshall M
    Invest New Drugs; 2014 Apr; 32(2):213-26. PubMed ID: 24114124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
    Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H
    J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHK1 regulates NF-κB signaling upon DNA damage in p53- deficient cells and associated tumor-derived microvesicles.
    Carroll BL; Pulkoski-Gross MJ; Hannun YA; Obeid LM
    Oncotarget; 2016 Apr; 7(14):18159-70. PubMed ID: 26921248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation.
    Gomes LR; Rocha CRR; Martins DJ; Fiore APZP; Kinker GS; Bruni-Cardoso A; Menck CFM
    Cell Death Dis; 2019 Jun; 10(6):459. PubMed ID: 31189884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ribonucleoside AICAr induces differentiation of myeloid leukemia by activating the ATR/Chk1 via pyrimidine depletion.
    Dembitz V; Tomic B; Kodvanj I; Simon JA; Bedalov A; Visnjic D
    J Biol Chem; 2019 Oct; 294(42):15257-15270. PubMed ID: 31431503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breast cancer treatment.
    Chung SW; Kim GC; Kweon S; Lee H; Choi JU; Mahmud F; Chang HW; Kim JW; Son WC; Kim SY; Byun Y
    Biomaterials; 2018 Nov; 182():35-43. PubMed ID: 30103170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells.
    Ando K; Nakamura Y; Nagase H; Nakagawara A; Koshinaga T; Wada S; Makishima M
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31362335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
    Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
    Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Zhao E; Jiang X; Cui H
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30200251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition.
    Mathur D; Stratikopoulos E; Ozturk S; Steinbach N; Pegno S; Schoenfeld S; Yong R; Murty VV; Asara JM; Cantley LC; Parsons R
    Cancer Discov; 2017 Apr; 7(4):380-390. PubMed ID: 28255082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
    Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H
    Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down regulation of Chk1 by p53 plays a role in synergistic induction of apoptosis by chemotherapeutics and inhibitors for Jak2 or BCR/ABL in hematopoietic cells.
    Umezawa Y; Kurosu T; Akiyama H; Wu N; Nogami A; Nagao T; Miura O
    Oncotarget; 2016 Jul; 7(28):44448-44461. PubMed ID: 27286446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress.
    Zhang Y; Lai J; Du Z; Gao J; Yang S; Gorityala S; Xiong X; Deng O; Ma Z; Yan C; Susana G; Xu Y; Zhang J
    Oncotarget; 2016 Jun; 7(23):34688-702. PubMed ID: 27167194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control.
    Demidova AR; Aau MY; Zhuang L; Yu Q
    J Biol Chem; 2009 Feb; 284(7):4132-9. PubMed ID: 19060337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
    Kim HJ; Min A; Im SA; Jang H; Lee KH; Lau A; Lee M; Kim S; Yang Y; Kim J; Kim TY; Oh DY; Brown J; O'Connor MJ; Bang YJ
    Int J Cancer; 2017 Jan; 140(1):109-119. PubMed ID: 27501113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Withaferin A inhibits expression of ataxia telangiectasia and Rad3-related kinase and enhances sensitivity of human breast cancer cells to cisplatin.
    Hahm ER; Lee J; Abella T; Singh SV
    Mol Carcinog; 2019 Nov; 58(11):2139-2148. PubMed ID: 31441116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.